Fred Alger Management LLC Has $37.61 Million Stock Holdings in Adaptive Biotechnologies Corporation $ADPT

Fred Alger Management LLC lifted its holdings in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 6.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,514,234 shares of the company’s stock after purchasing an additional 158,807 shares during the period. Fred Alger Management LLC owned 1.65% of Adaptive Biotechnologies worth $37,613,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Sound Income Strategies LLC bought a new stake in Adaptive Biotechnologies in the third quarter worth approximately $30,000. Smartleaf Asset Management LLC boosted its holdings in shares of Adaptive Biotechnologies by 593.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock worth $59,000 after buying an additional 3,371 shares in the last quarter. Caxton Associates LLP bought a new position in shares of Adaptive Biotechnologies during the 1st quarter worth approximately $93,000. Quadrant Capital Group LLC acquired a new stake in shares of Adaptive Biotechnologies during the 3rd quarter worth approximately $133,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Adaptive Biotechnologies during the 2nd quarter worth approximately $134,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Piper Sandler set a $21.00 price target on shares of Adaptive Biotechnologies in a report on Friday, February 6th. BTIG Research lifted their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Wall Street Zen lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.25.

Insider Activity

In related news, insider Francis Lo sold 79,590 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $17.73, for a total value of $1,411,130.70. Following the sale, the insider owned 315,978 shares in the company, valued at $5,602,289.94. This represents a 20.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Julie Rubinstein sold 141,583 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $13.29, for a total transaction of $1,881,638.07. Following the completion of the transaction, the chief operating officer directly owned 516,610 shares in the company, valued at approximately $6,865,746.90. The trade was a 21.51% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 2,350,698 shares of company stock valued at $34,449,277. 6.40% of the stock is currently owned by insiders.

Adaptive Biotechnologies News Roundup

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Recent fundamental backdrop: Adaptive’s Feb. 5 quarterly report showed an EPS beat and revenue that was up ~51% year-over-year, supporting investor confidence heading into March. MarketBeat ADPT profile
• Neutral Sentiment: Short-interest print for March shows 0 shares and NaN changes (likely a reporting error). That data point provides no clear bearish signal and may have contributed to lower perceived short pressure. (No reliable short-interest signal.)
• Negative Sentiment: Significant insider selling on Mar. 11–13: combined, company executives and insiders sold roughly 1.25M shares for about $16.6M in proceeds, materially reducing several insiders’ stakes (examples below). This coordinated selling can be perceived negatively by investors as supply into the market or insiders taking liquidity. Filings: CEO Chad M. Robins (470,167 sh, ~$6.19M) Chad Robins Form 4; Harlan S. Robins (470,266 sh, ~$6.19M) Harlan Robins Form 4; COO Julie Rubinstein (160,643 sh across filings) Julie Rubinstein Form 4; CFO Kyle Piskel (18,672 sh) Kyle Piskel Form 4; Sharon Benzeno (63,103 sh) Sharon Benzeno Form 4; Susan Bobulsky (41,338 sh) Susan Bobulsky Form 4; Francis Lo (30,593 sh) Francis Lo Form 4.

Adaptive Biotechnologies Stock Up 5.8%

Shares of NASDAQ:ADPT opened at $13.17 on Monday. Adaptive Biotechnologies Corporation has a twelve month low of $6.68 and a twelve month high of $20.76. The stock’s 50 day moving average is $16.55 and its 200-day moving average is $15.89. The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of -32.92 and a beta of 2.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The business had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. During the same quarter last year, the firm posted ($0.23) EPS. Adaptive Biotechnologies’s revenue was up 51.0% compared to the same quarter last year. Equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.